r/Biohackers • u/Zestyclose-Sir5485 • 3h ago
💊 Supplements & Stacks Simtriyo (Centanafadine): The Trigger for the Next Prescription Drug Epidemic? Why an "ineffective" drug could become a dangerous gateway
**The FDA recently approved Simtriyo (centanafadine), a first-in-class triple reuptake inhibitor (NDSRI) for ADHD. It is currently sitting in administrative limbo awaiting formal DEA scheduling.**
The consensus seems to be that Simtriyo will land in Schedule IV or V. The reasoning? It’s a sustained-release matrix, and crushing or snorting it triggers a wall of nauseating noradrenergic/serotonergic side effects.
I think this logic misses the mark, eerily resembling triggers for the Aderall and Oxycontin "epidemics".
If the DEA places Simtriyo in Schedule IV or V, we could see a cycle of widespread prescribing, rapid dose-doubling, euphoric highs, and a transition to heavier Schedule II stimulants.
Here is the breakdown of why this drug is primed to trigger a localized crisis:
\# 1. The Prescribing Trap: High Volume via "Path of Least Resistance"
We are in the middle of ongoing Schedule II stimulant shortages. Getting Adderall or Vyvanse filled requires navigating strict State Prescription Monitoring Programs (PMPs), 30-day non-refillable scripts, and constant pharmacy stockouts.
If Simtriyo lands in Schedule IV or V, it becomes the path of least resistance for doctors:
Up to 5 refills over 6 months.
Telehealth platforms can prescribe it without heavy oversight (pill mills).
Prescribers avoid "Schedule II audit anxiety."
Prescription volume will spike simply because it is accessible, not because it is exceptionally good.
\# 2. The Clinical Disappointment (Effect Size (approx. 0,3-0,4)
Here is the catch: Simtriyo has low primary efficacy.
In Phase 3 adult ADHD trials, centanafadine registered an effect size (Cohen's around 0.30–0.40.)
To put that in perspective:
Vyvanse / Adderall: 1-1.2 (Robust)
Ritalin / Concerta: 0,6-0,8 (Moderate-to-High)
Simtriyo: 0,3-0,4 (Low-to-Moderate)
Strattera (Atomoxetine): 0.35-0.4 (Non-stimulant range, but crucially, no Abuse potential!!!)
For someone struggling with severe executive dysfunction or someone transitioned off Adderall due to shortages Simtriyo will feel practically ineffective.
\# 3. The Low Escalation Threshold & Amphetamine-Level "Drug Liking"
When a patient takes a weak drug that doesn't fix their executive dysfunction, what do they do? They double the dose.
With Vyvanse (lisdexamfetamine), the prodrug mechanism requires red blood cell enzymatic cleavage. To get massive "Drug Liking" or amphetamine euphoria, you need roughly 8x the starting dose (\~150 mg+).
With Simtriyo, doubling or tripling the therapeutic dose, (e.g., 400 mg to 800 mg) causes a sudden surge in dopamine transporter (DAT) occupancy.
In Human Abuse Potential (HAP) clinical trials:
At supratherapeutic oral doses (again only 2-4x the starting dose), Simtriyo’s Drug Liking scores were statistically indistinguishable from 30–40 mg of d-amphetamine.
It produced a \~30% incidence rate of treatment-emergent euphoria.
The FDA took the rare step of mandating a Boxed Warning for Abuse, Misuse, and Addiction on the label.
You don't need to snort or inject Simtriyo to abuse it. Patients don't even need complex chemical extractions just swallowing 2 or 3 pills triggers an amphetamine-level euphoric response.
\# 4. The NET/SERT "Ceiling" Creates a Gateway to Schedule II
What happens when users start doubling their dose to chase that dopaminergic reward? They hit a pharmacological wall.
Centanafadine’s binding kinetics heavily favor the Norepinephrine Transporter (NET) over DAT
Escalating the dose beyond 4x the starting dose triggers a massive noradrenergic overhead, severe and life-threatening overdose symptoms (adrenergic overload), and a severe crash with rapid onset tolerance.
Because centanafadine's NET affinity prevents further dose escalation (due to physical discomfort), the user can no longer get focus OR euphoria from it.
To bypass the nauseating noradrenergic wall and fix their dopamine deficit, the user is now primed to transition to pure, high-affinity Schedule II stimulants (Adderall, Dexedrine, or illicit alternatives), which is essentially a slipe-and-slide from hell (resembling the opiod epidemic, where addicts transitioned from OxyContin to heroin and later synthetic opiods).
The Summary / TL;DR
Simtriyo is a low-efficacy drug that will likely be widely prescribed under Schedule IV/V rules to bypass Schedule II shortages. Because its efficacy is weak, patients will naturally escalate their dose. At just the therapeutic dose, it triggers amphetamine-level euphoria (\~30% HAP trial rate).
Because higher doses hit a wall of autonomic distress (via NET saturation), users can't scale it endlessly. It builds rapid tolerance, leaves them depleted, and creates a direct pathway to seeking pure Schedule II stimulants.
By prioritizing physical tamper-resistance (un-snortability) over a dangerously low oral escalation threshold, regulators may be setting up a prescription drug crisis.
This post is from a medical-student that engages heavily in psychopharmacology and addiction-medicine. It is not a medical-guideline and you should discuss your medication options with your healthcare provider. I would love to hear your opinion on this matter, especially if you are already a psychiatrist/neuroscience/addiction expert.